Effects of Antidiabetic Drugs on Gut Microbiota Composition
Open accessThe DOI matches its Crossref record; 82 of the 85 references it cites were found in a registry or an index.
Abstract
Gut microbiota forms a catalog of about 1000 bacterial species; which mainly belong to the Firmicutes and Bacteroidetes phyla. Microbial genes are essential for key metabolic processes; such as the biosynthesis of short-chain fatty acids (SCFA); amino acids; bile acids or vitamins. It is becoming clear that gut microbiota is playing a prevalent role in pathologies such as metabolic syndrome; type 2 diabetes (T2D); inflammatory and bowel diseases. Obesity and related diseases; notably type 2 diabetes, induce gut dysbiosis. In this review; we aim to cover the current knowledge about the effects of antidiabetic drugs on gut microbiota diversity and composition as well as the potential beneficial effects mediated by specific taxa. Metformin is the first-line treatment against T2D. In addition to its glucose-lowering and insulin sensitizing effects, metformin promotes SCFA-producing and mucin-degrading bacteria. Other antidiabetic drugs discussed in this review show positive effects on dysbiosis; but without any consensus specifically regarding the Firmicutes to Bacteroidetes ratio. Thus, beneficial effects might be mediated by specific taxa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the most studied medication is metformin, which seems to positively influence microbiota diversity and composition [61].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [61]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 5×
“High-fat diet promotes taxa belonging to the Firmicutes (Clostridium ramosum) and Proteobacteria (Bilophila wadsworthia), while high-fiber diet increases the abundance in Bacteroidetes (Prevotella, Xylanibactera), Verrucomicrobia (Akkermansia muciniphila) and Actinobacteria (Bifidobacterium spp.) and decreases the amo…”
BackgroundInfluentialDiet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100 · cited 1×
“Gut microbiota composition and diversity is predominantly influenced by the diet [6,34,42].”
BackgroundHuman gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
Diversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913 · cited 2×
“They are modulated by the diet, host health, age, ethnicity and genetics and thus are unique and highly variable among individuals [2,3].”
BackgroundA core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823 · cited 1×
“Nevertheless, Turnbaugh and colleagues [4] suggest that there is a “core gut microbiome” (i.”
BackgroundHuman gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815 · cited 2×
“They are modulated by the diet, host health, age, ethnicity and genetics and thus are unique and highly variable among individuals [2,3].”
BackgroundEckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176
De Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579 · cited 6×
“Whereas Escherichia probably plays an important role in the side-effects of metformin [19], Bifidobacterium adolescentis has been shown to negatively correlate to HbA1c.”
BackgroundInfluentialEckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Cited by
Yuan, T., Yang, T., Chen, H., Fu, D., Hu, Y., Wang, J., Yuan, Q., Yu, H., Xu, W., & Xie, X. (2019) · Redox Biology · doi:10.1016/j.redox.2018.09.025 · Cited by 743
“The abundance of the gut microbiota also improves with metformin treatment in humans [189].”
BackgroundArmanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
Gut microbiota influence in type 2 diabetes mellitus (T2DM)
Cunningham, A. L., Stephens, J. W., & Harris, D. A. (2021) · Gut Pathogens · doi:10.1186/s13099-021-00446-0 · Cited by 270
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Salguero, M., Al‑Obaide, M., Singh, R., Siepmann, T., & Vasylyeva, T. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7943 · Cited by 257
“Metformin, a blood glucose regulator, was reported to increase the relative abundance of LPS-producing Gram-negative gut bacteria (22).”
Lee, D. M., Battson, M. L., Jarrell, D. K., Hou, S., Ecton, K. E., Weir, T. L., & Gentile, C. L. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0708-x · Cited by 246
“For example, various drug classes have been shown to profoundly alter gut microbiota composition [25, 26]; and the gut microbiota can alter drug absorption and metabolism or mediate some of the physiological effects of T2D medications [25, 27].”
BackgroundCrosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy
Campbell, C., Kandalgaonkar, M. R., Golonka, R. M., Yeoh, B. S., Vijay-Kumar, M., & Saha, P. (2023) · Biomedicines · doi:10.3390/biomedicines11020294 · Cited by 243
SGLT2 Inhibitor–Induced Sympathoinhibition
Herat, L. Y., Magno, A. L., Rudnicka, C., Hricova, J., Carnagarin, R., Ward, N. C., Arcambal, A., Kiuchi, M. G., Head, G. A., Schlaich, M. P., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.11.007 · Cited by 233
“There is growing interest in the role the gut microbiota plays in the pathology of the metabolic syndrome and type 2 diabetes (33).”
BackgroundAltered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?
Sircana, A., Framarin, L., Leone, N., Berrutti, M., Castellino, F., Parente, R., De Michieli, F., Paschetta, E., & Musso, G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1057-6 · Cited by 223
Liraglutide modulates gut microbiota and reduces NAFLD in obese mice
Moreira, G., Azevedo, F., Ribeiro, L., Santos, A., Guadagnini, D., Gama, P., Liberti, E., Saad, M., & Carvalho, C. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.07.009 · Cited by 156
Antibiotic-induced collateral damage to the microbiota and associated infections
de Nies, L., Kobras, C. M., & Stracy, M. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00936-9 · Cited by 169
Liu, H., Zhang, M., Ma, Q., Tian, B., Nie, C., Chen, Z., & Li, J. (2020) · Food & Function · doi:10.1039/d0fo00855a · Cited by 136
GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Deng, X., Zhang, C., Wang, P., Wei, W., Shi, X., Wang, P., Yang, J., Wang, L., Tang, S., Fang, Y., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac210 · Cited by 126
“It has also been reported that several antidiabetic drugs such as metformin, acarbose, and liraglutide partly achieve their glucose-lowering effects and additional metabolic improvements by modulating the gut microbiota and its metabolites (12-15).”
BackgroundSomm, E., Montandon, S. A., Loizides-Mangold, U., Gaïa, N., Lazarevic, V., De Vito, C., Perroud, E., Bochaton-Piallat, M.-L., Dibner, C., Schrenzel, J., et al. (2021) · Translational Research · doi:10.1016/j.trsl.2020.07.008 · Cited by 118
“In turn, GLP-1R agonism can modify intestinal bacteria populations.(14,43) In this context, we MCD MCD/ Lira Cer C16 SM C24”
BackgroundSelf-citationGut-Brain Axis: Role of Microbiome, Metabolomics, Hormones, and Stress in Mental Health Disorders
Verma, A., Inslicht, S. S., & Bhargava, A. (2024) · Cells · doi:10.3390/cells13171436 · Cited by 161
“Interestingly, although it is uncommon for an antidiabetic drug to alter the microbiome, a study by Wang et al. demonstrated that treatment with liraglutide in mice led to significant changes in bacterial composition [226].”
BackgroundOnal, E. M., Afşar, B., Covic, A. C., Vaziri, N. D., & Kanbay, M. (2018) · Hypertension Research · doi:10.1038/s41440-018-0144-z · Cited by 122
Chai, Y., Luo, J., & Bao, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112155 · Cited by 107
The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus
Crăciun, C.-I., Neag, M. A., Cătinean, A., Mitre, A. O., Rusu, A., Bala, C. G., Román, G., Buzoianu, A. D., Muntean, D. M., & Craciun, A. E. (2022) · Biomedicines · doi:10.3390/biomedicines10020308 · Cited by 105
The alteration of gut microbiota in newly diagnosed type 2 diabetic patients
Chen, P., Chien, Y., & Yang, S. (2018) · Nutrition · doi:10.1016/j.nut.2018.11.019 · Cited by 98
Zhang, M., Feng, R., Yang, M., Cheng, Q., Wang, Z., Liu, W., & Ma, J. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000717 · Cited by 94
“tended to decline after thiazolidinediones (TZD), pioglitazone treatment in the high-fat diet-fed rats.(5) 26 The”
BackgroundGut microbiota, hypertension and chronic kidney disease: Recent advances
Sircana, A., Michieli, F. D., Parente, R., Framarin, L., Leone, N., Berrutti, M., Paschetta, E., Bongiovanni, D., & Musso, G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.013 · Cited by 97
Probiotics for the treatment of type 2 diabetes: A review of randomized controlled trials
Tiderencel, K. A., Hutcheon, D. A., & Ziegler, J. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3213 · Cited by 82
Crosstalk between gut microbiota and antidiabetic drug action
Kyriachenko, Y., Falalyeyeva, T. M., Korotkyi, O., Molochek, N., & Kobyliak, N. M. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i3.154 · Cited by 85
Modulation of gut‐microbiota through probiotics and dietary interventions to improve host health
Dasriya, V. L., Samtiya, M., Ranveer, S. A., Dhillon, H. S., Devi, N., Sharma, V., Nikam, P., Puniya, M., Chaudhary, P., Chaudhary, V., et al. (2024) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.13370 · Cited by 93
de Paiva, I. H. R., da Silva, R. S., Mendonça, I. P., de Souza, J. R. B., & Peixoto, C. A. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10142-w · Cited by 75
“GLP-1R agonists affect the composition of the microbiota by altering gastric emptying rate and timing, as well as the intestinal lumen’s internal environment, includ - ing local pH levels and nutrient availability (Montandon and Jornayvaz 2017 ).”
Umirah, F., Neoh, C. F., Ramasamy, K., & Lim, S. M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108689 · Cited by 84
The Gut Microbiome, Metformin, and Aging
Induri, S. N. R., Kansara, P., Thomas, S. C., Xu, F., Saxena, D. B., & Li, X. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051920-093829 · Cited by 71
Gupta, S., & Sen, U. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104391 · Cited by 83
Gowd, V., Xie, L., Zheng, X., & Chen, W. (2019) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2019.1576025 · Cited by 73
“Metformin has been used as a first line oral antidiabetic drug for over 60 years to treat DM patients [35,74].”
BackgroundEjtahed, H.-S., Tito, R. Y., Siadat, S.-D., Hasani-Ranjbar, S., Hoseini-Tavassol, Z., Rymenans, L., Verbeke, K., Soroush, A.-R., Raes, J., & Larijani, B. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0826 · Cited by 63
Caenepeel, C., Tabib, N. S. S., Vieira‐Silva, S., & Vermeire, S. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16096 · Cited by 72
Liu, W., Luo, Z., Zhou, J., & Sun, B. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.853771 · Cited by 78
Pharmacologic and Nonpharmacologic Therapies for the Gut Microbiota in Type 2 Diabetes
Caesar, R. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.01.007 · Cited by 58
Type 2 diabetes, gut microbiome, and systems biology: A novel perspective for a new era
Martínez-López, Y. E., Esquivel-Hernandez, D. A., Sánchez-Castañeda, J. P., Neri-Rosario, D., Guardado‐Mendoza, R., & Reséndis-Antonio, O. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2111952 · Cited by 65
“Alternatively, when the nonfermentable fiber is limited in the distal large intestine, the luminal pH is raised to 6.5, eliminating butyrate-producing bacteria almost entirely.24 GM uses major bacterial metabolic pathways (Embden-Meyerhof-Parnas, pentoses-phosphate, Wood-Ljungdahl, succinate, acrylate, and propanediol…”
BackgroundInfluentialAnti-diabetics and antimicrobials: Harmony of mutual interplay
Hegazy, W. A. H., Rajab, A. A. H., Lila, A. S. A., & Abbas, H. A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i11.1832 · Cited by 59
Shao, J., Liu, Y., Wang, H., Luo, Y., & Chen, L. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1805418 · Cited by 62
“Escherichia coli can produce tryptophan, Lactobacillus, which is a type of probiotics that links with insulin secretion, can produce AhR ligands, and has high capability to metabolize tryptophan, thereby influencing SCFAs alteration and activating the intestine-brain axis [33, 34].”
BackgroundDapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model
Yang, M., Shi, F., Liu, W., Zhang, M.-C., Feng, R., Cheng, Q., Liu, W., & Ma, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00635 · Cited by 56
“It can be modulated by diet, host health, age, ethnicity, genetics, and antidiabetic medication (4).”
BackgroundMcMurdie, P. J., Stoeva, M. K., Justice, N., Nemchek, M. P., Sieber, C. M. K., Tyagi, S., Gines, J., Skennerton, C. T., Souza, M., Kolterman, O., et al. (2022) · BMC Microbiology · doi:10.1186/s12866-021-02415-8 · Cited by 58
“Data on the microbiome impact of sulfonylurea drug class is notably lacking [56].”
BackgroundNatural Alkaloids Intervening the Insulin Pathway: New Hopes for Anti-Diabetic Agents?
Christodoulou, M., Tchoumtchoua, J., Skaltsounis, A., Scorilas, A., & Halabalaki, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180430152618 · Cited by 53
Cao, T. T. B., Wu, K., Hsu, J., Chang, C., Chou, C., Lin, C.-Y., Liao, Y.-M., Lin, P.-C., Yang, L., & Lin, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573891 · Cited by 54
“Previous reviews have suggested the effects of anti-hyperglycemic drugs on gut microbiota (8, 11, 13), however, the differences in results between human and animal studies have not been differentiated.”
BackgroundChen, Y., Shen, X., Ma, T., Yu, X., Kwok, L. Y., Li, Y., Sun, Z., Li, D., & Zhang, H. (2023) · mSystems · doi:10.1128/msystems.01300-22 · Cited by 55
Mechanism of the antidiabetic action of Nigella sativa and Thymoquinone: a review
Shaukat, A., Zaidi, A., Anwar, H., & Kizilbash, N. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1126272 · Cited by 67
“Metf, the mainstream glucose-lowering medication for DM, ameliorates gut dysbiosis (359, 360).”
BackgroundGut microbiota and therapy for obesity and type 2 diabetes
Zhang, L., Wang, P., Huang, J., Xing, Y., Wong, F. S., Suo, J., & Li, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1333778 · Cited by 75
“Other prominent drugs include chronically administered drugs that include anti-diabetic medications, such as metformin, which alter the gut microbiota (56).”
BackgroundCheng, X., Zhang, Y., Li, Y., Wu, Q., Wu, J., Park, S., Guo, C., & Lu, J. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02686-9 · Cited by 50
“As these genera are the butyrate-producing genera [19, 49, 50], the associations between gut dysbiosis and SARS-CoV-2 infection may be partly mediated by short-chain fatty acids (SCFAs), mainly acetate, propionate and butyrate, which play vital roles in maintaining mucosal integrity and exerting antiinflammatory effec…”
BackgroundAkkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders
Kobyliak, N. M., Falalyeyeva, T. M., Kyriachenko, Y., TSEYSLYER, Y., KOVALCHUK, O., HADILIIA, O., Eslami, M., YOUSEFI, B., Abenavoli, L., Fagoonee, S., et al. (2022) · Minerva Endocrinology · doi:10.23736/s2724-6507.22.03752-6 · Cited by 50
Gut microbiota profile in healthy Indonesians
Rahayu, E. S., Utami, T., Mariyatun, M., Hasan, P. N., Kamil, R. Z., Setyawan, R. H., Pamungkaningtyas, F. H., Harahap, I. A., Wiryohanjoyo, D. V., Pramesi, P. C., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i12.1478 · Cited by 50
Yin, Y., Sripetchwandee, J., Chattipakorn, N., & Chattipakorn, S. C. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102361 · Cited by 46
Ahmed, L. A., Salem, M. B., el-Din, S. H. S., El-Lakkany, N. M., Okasha, H., Nasr, S. M., Hammam, O. A., Botros, S. S., & Saleh, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173461 · Cited by 41
Role of Gut Microbial Metabolites in Cardiovascular Diseases—Current Insights and the Road Ahead
Datta, S., Pasham, S., Sandeep, I. S., Boini, K. M., & Koka, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810208 · Cited by 46
Wang, Y., Jia, X., & Cong, B. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1396031 · Cited by 50
“Intestinal microbiota plays a crucial role in many key metabolic processes of human body, such as SCFAs, amino acids, bile acids and vitamin synthesis (Montandon and Jornayvaz, 2017).”
BackgroundKobyliak, N. M., Abenavoli, L., Mykhalchyshyn, G., Falalyeyeva, T. M., Tsyryuk, O., Kononenko, L., Kyriienko, D., & Komisarenko, I. (2019) · Clinical Diabetology · doi:10.5603/dk.2019.0016 · Cited by 38
Role and effective therapeutic target of gut microbiota in NAFLD/NASH (Review)
Liu, Q., Liu, S., Chen, L., Zhao, Z., Du, S.-X., Dong, Q., Xin, Y., & Xuan, S. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7781 · Cited by 51
Kant, R., Chandra, L., Verma, V. K., Nain, P., Bello, D., Patel, S., Ala, S., Chandra, R., & Antony, M. A. (2022) · World Journal of Methodology · doi:10.5662/wjm.v12.i4.246 · Cited by 39
Tsai, H.-J., Hung, W., Hung, W., Lee, Y.-J., Chen, Y.-C., Lee, C., Tsai, Y., & Dai, C. (2023) · Nutrients · doi:10.3390/nu15071712 · Cited by 40
Choi, Y., Bose, S., Shin, N. R., Song, E., Nam, Y., & Kim, H. (2020) · Nutrients · doi:10.3390/nu12020276 · Cited by 35
da Silva, R. S., de Paiva, I. H. R., Mendonça, I. P., de Souza, J. R. B., Lucena‐Silva, N., & Peixoto, C. A. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01603-y · Cited by 39
“…microbial composition by influencing the gastric emptying rate, the gut transit time, and the internal environment of the gut lumen (pH levels and nutrient availability) (Grasset et al. 2017; Montandon and Jornayvaz 2017; Wang et al. 2017; Zhao et al. 2018; Madsen et al. 2019; Shang et al. 2021).”
Huang, Y., Lou, X., Jiang, C., Ji, X., Tao, X., Sun, J., & Bao, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1044030 · Cited by 35
Kusnadi, Y., Saleh, M. I., Ali, Z., Hermansyah, H., Murti, K., Hafy, Z., & Yuristo, E. (2023) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2023.10478 · Cited by 32
“Anti-diabetic medication including biguanides, alphaglucosidase inhibitors, incretin agents, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and thiazolidinediones could influence the gut microbiota [22].”
BackgroundFarup, P. G., Lydersen, S., & Valeur, J. (2019) · Journal of Obesity · doi:10.1155/2019/4608315 · Cited by 29
Does Gut-Microbiome Interaction Protect against Obesity and Obesity-Associated Metabolic Disorders?
Zawada, A. E., Rychter, A. M., Ratajczak, A. E., Lisiecka-Masian, A., Dobrowolska, A., & Krela‐Kaźmierczak, I. (2020) · Microorganisms · doi:10.3390/microorganisms9010018 · Cited by 30
Li, X., Chen, W., Gao, J., Gao, W., Zhang, Y., Zeng, H., & Zheng, B. (2023) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2023.108501 · Cited by 28
Targeting the Gut Microbiota for Prevention and Management of Type 2 Diabetes
Zeppa, S. D., Gervasi, M., Bartolacci, A., Ferrini, F., Patti, A., Sestili, P., Stocchi, V., & Agostini, D. (2024) · Nutrients · doi:10.3390/nu16223951 · Cited by 35
“T2D and obesity are known to induce gut dysbiosis, while antidiabetic drugs can help to restore a healthy microbiota [88].”
Ding, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 31
“It is known thatmetformin can increase peripheral glucose uptake and modulate the incretin pathway by improving GLP1 receptor expression in the pancreatic islets and increasing plasma levels of GLP-1 (Viollet et al., 2012; Pernicova and Korbonits, 2014; Montandon and Jornayvaz, 2017).”
BackgroundLiu, A., Lin, W., Ming, R., Guan, W., Wang, X., Hu, N., & Ren, Y. (2022) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2022.129142 · Cited by 30
Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice
Herat, L. Y., Ward, N. C., Magno, A. L., Rakoczy, E. P., Kiuchi, M. G., Schlaich, M. P., & Matthews, V. B. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i23.0000 · Cited by 28
Savytska, M., Kyriienko, D., Komisarenko, I., Kovalchuk, O. I., Falalyeyeva, T. M., & Kobyliak, N. M. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01474-6 · Cited by 31
“…inhibitors, GLP-1 agonists, DPP4 inhibitors, and sodium/glucose cotransporter (SGLT) inhibitors can change the gut microbiota composition [25, 26], before approving the research project we considered therapy with these antidiabetic drugs at least 3 months before randomization as an exclusion…”
BackgroundChen, Y., & Wang, M. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s334325 · Cited by 26
Ahmed, L. A., & Al‐Massri, K. F. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220222105004 · Cited by 26
Liaqat, I., Ali, N. M., Arshad, N., Sajjad, S., Rashid, F., Hanif, U., Ara, C., Ulfat, M., Andleeb, S., Awan, M. U. F., et al. (2023) · Brazilian Journal of Biology · doi:10.1590/1519-6984.242818 · Cited by 31
“…extensively used antidiabetic drug resulted in increased number of short chain fatty acids (SCFA) producing bacteria including ( Prevotella , Bacteroides , Butyricoccus and Blautia etc.) with positive effects on the Proteobacteria phylum and Lactobacillus genera (Montandon and Jornayvaz, 2017).”
BackgroundBica, I.-C., Pietroșel, V.-A., Salmen, T., Diaconu, C.-T., Fierbinteanu-Braticevici, C. G., Stoica, R. A., Suceveanu, A., & Stoian, A. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087184 · Cited by 27
The role of gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy
Xie, L., & Lin, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604315 · Cited by 28
The role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
The impact of sodium-glucose cotransporter inhibitors on gut microbiota: a scoping review
Afşar, B., Afşar, R. E., & Lentine, K. L. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01435-1 · Cited by 27
“Thus, microbiota may be changed and modulated by diet, health status, age, ethnicity, genetics and medications [9].”
Kanbay, M., Al-Shiab, R., Shah, E., Özbek, L., Güldan, M., Ortíz, A., & Fouque, D. P. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf351 · Cited by 28
“The SCFAs acetate, propionate, and butyrate are among the most studied microbial metabolites; they bind to G-protein-coupled receptors and regulate energy metabolism, appetite, and glucose balance [12 ].”
InfluentialGluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology
Brønden, A., & Knop, F. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz025 · Cited by 22
Wei, B., Wang, Y., Xiang, S., Jiang, Y., Chen, R., & Hu, N. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00471.2020 · Cited by 23
Microbiome Changes after Type 2 Diabetes Treatment: A Systematic Review
Merkevičius, K., Kundelis, R., Maleckas, A., & Veličkienė, D. (2021) · Medicina · doi:10.3390/medicina57101084 · Cited by 20
Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome
Ермоленко, Е. И., Симаненкова, А. В., Alferova, L. S., Lavrenova, N. S., Kotyleva, M., Минасян, С. М., Chernikova, A. T., Тимкина, Н. В., Сергеевич, Г. Н., Dmitriev, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126837 · Cited by 18
Madsen, M. S. A., Grønlund, R. V., Eid, J. S., Christensen‐Dalsgaard, M., Sommer, M. O. A., Rigbolt, K. T. G., Madsen, M. R., Jelsing, J., Vrang, N., Hansen, H. H., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110966 · Cited by 18
Lorcaserin and phentermine exert anti-obesity effects with modulation of the gut microbiota
Song, E., Shin, N. R., Jeon, S., Nam, Y., & Kim, H. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1109651 · Cited by 16
“Metformin, a first-line clinical medicine for T2DM, enhanced the relative abundance of Akkermansia, which has the potential for glucose metabolism and insulin modulation (Shin et al., 2014; Montandon and Jornayvaz, 2017).”
BackgroundLee, S.-E., Choi, Y., Jun, J. E., Lee, Y., Jin, S., Hur, K. Y., Ko, G. P., & Lee, M. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0090 · Cited by 20
“The compositions and abundance of microbiota are affected by commonly used antidiabetic agents such as metformin and sulfonylureas [12,14-20].”
BackgroundGut microbiota on cardiovascular diseases-a mini review on current evidence
Zhang, S., Li, J., Li, L., & Yuan, X. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1690411 · Cited by 18
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies
Sharma, A. K., Sharma, A., Lal, S., Kumar, A., Yadav, N. K., Tabassum, F., Akhtar, M. S., Imam, M. T., Almalki, Z. S., & Mukherjee, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103558 · Cited by 15
Schots, P. C., Jansen, K. M., Mrázek, J., Pedersen, A. M., Olsen, R. L., & Larsen, T. S. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.09.002 · Cited by 17
Influence of the Intestinal Microbiota on Diabetes Management
Alvarez-Vieites, E., López-Santamarina, A., Miranda, J. M., Mondragón, A. D. C., Lamas, A., Cardelle‐Cobas, A., Nebot, C., Franco, C. M., & Cepeda, A. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200514220950 · Cited by 14
Fueling the fire: colonocyte metabolism and its effect on the colonic epithelia
Martínez-Ruiz, M., Robeson, M. S., & Piccolo, B. D. (2025) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2025.2507701 · Cited by 20
“Other dietary and pharmacologically derived compounds have been noted to influence SCFA production and/or SCFA-producing bacteria, such as poly-phenols, metformin, and other pharmaceutical agents (Montandon and Jornayvaz 2017).”
Portal Vein Thrombosis in Patients with Liver Cirrhosis: What Went Wrong?
Georgescu, D., Ancusa, O., Azoulay, D., Lascu, A., Ioniță, I., Călămar-Popovici, D., Ionita, M., Rosca, C. I., Brează, G. M., Reisz, D., et al. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s413438 · Cited by 13
Wang, S., Zhang, X., Li, H., Ren, Y., Geng, Y., Lu, Z., Shi, J., & Xu, Z. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11548-9 · Cited by 14
Tang, Y., Yan, M., Fang, Z., Jin, S., & Xu, T. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003837 · Cited by 19
“This indicates that supplementation with specific probiotics may further improve the hypoglycemic effects of antidiabetics and be helpful for the development of new therapeutic drugs.”
BackgroundLi, X., Liang, J., Gao, W., Zhang, Y., Zeng, H., & Zheng, B. (2023) · Food Bioscience · doi:10.1016/j.fbio.2023.102931 · Cited by 12
Wang, Z., Ren, X., Peng, Z., Zeng, M., Wang, Z., Chen, Q., Chen, J., Dai, X., Christian, M., Qie, X., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120513 · Cited by 10
Metformin—mechanisms of its glycemia-reducing effect
Drewe, J., Foretz, M., & Krähenbühl, S. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100106 · Cited by 19
Kirschner, S. K., Ghane, P., Park, J. K., Simbo, S. Y., Ivanov, I. V., Braga-Neto, U., Have, G. A. M. T., Thaden, J. J., ENGELEN, M. P. K. J., & Deutz, N. E. P. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155399 · Cited by 12
Lorenzo, Ó., Crespo-Yanguas, M., Hang, T., Lumpuy‐Castillo, J., Hernandez, A. M., Llavero, C., García-Alonso, M., & Ruíz-Tóvar, J. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17197239 · Cited by 13
Andrei, C., Zanfirescu, A., Ormeneanu, V.-P., & Negreș, S. (2025) · Antibiotics · doi:10.3390/antibiotics14020138 · Cited by 13
“Conversely, metformin enhances SCFA production and alters the microbiota composition, increasing bacteria such as Enterobacte riaceae and Akkermansia muciniphila [51–53].”
Separating “good” from “bad” faecal dysbiosis – evidence from two cross-sectional studies
Farup, P. G., Aasbrenn, M., & Valeur, J. (2018) · BMC Obesity · doi:10.1186/s40608-018-0207-3 · Cited by 12
“The drug’s effect on the faecal microbiota is well established [4, 5, 11, 12].”
BackgroundChanges of intestinal microbiome and its relationship with painful diabetic neuropathy in rats
Jia, S., Mi, H., Yao, S., Liu, Y., Ming, Z., & Lin, J. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04015-2 · Cited by 10
“Specifically, gut microbiota in diabetes patients typically exhibit reduced diversity, a decrease in beneficial bacterial species (such as probiotics), and an increase in potentially harmful bacterial species [18].”
Huang, P., Wei, J. C., Liu, Y., Lin, C., Lin, C., & Chen, H. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14819 · Cited by 7
“In the LHDB, patients were defined as having T2DM if they satisfied any one of the following criteria for the 20032012 period: (1) patients with a diagnosis of diabetes or with a hypoglycaemic drug prescription during hospitalisation and (2) patients with (2a) two or more outpatient diagnosis of T2DM within 1 year or…”
MethodSavytska, M., Kyriienko, D., Zaychenko, G. V., Ostapchenko, D., Falalyeyeva, T. M., & Kobyliak, N. M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1276642 · Cited by 9
“Even though metformin can change the gut microbiota composition (25, 26), we did not exclude patients who took this drug in this study because metformin is currently recognized as a fi rst-line therapy in T2D patients.”
Background
Metadata
- Authors
- Montandon, S., & Jornayvaz, F.
- Affiliations
- University Hospital of Geneva (CH)
- Corresponding author
- Jornayvaz, François
- ORCID
- Jornayvaz, François
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2017-09-30
- Volume
- 8
- Issue
- 10
- Pages
- 250
- ISSN
- 2073-4425 (ISSN-L)
- PMC
- PMC5664100
- OpenAlex
- W2756853277
- Cited by
- 135
- References
- 85
- Citations by year
- 2025: 17 · 2024: 14 · 2023: 20 · 2022: 16 · 2021: 17 · 2020: 20 · 2019: 16 · 2018: 14 · 2017: 1
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Genes (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Novo Nordisk
- Gottfried und Julia Bangerter-Rhyner-Stiftung
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut microbiota, antidiabetic drugs, type 2 diabetes, metformin, short-chain fatty acids, gut dysbiosis, Firmicutes/Bacteroidetes ratio, mucin-degrading bacteria, obesity, microbial taxa, bile acids, insulin sensitivity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.